LenioBio GmbH
LenioBio is a life science biotech offering a disruptive protein expression technology. ALiCE is the first eukaryotic cell-free protein expression platform that is scalable and changes the way proteins are produced today, across all industries. ALiCE enables the discovery, development and production of difficult-to-express proteins. Our Head Office in Düsseldorf as well as our Technology & Innovation Center in Aachen are home to our international team who are working on how to have a positive impact on the issues facing the world.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
About Us
LenioBio announces the successful scaling of the ALiCE lysate manufacture and cell-free protein synthesis reaction – a world first for eukaryotic cell-free expression.
In February 2022, LenioBio completes the Horizon 2020 PEPPER project on time – one of the few recipients of this prestigious grant to do so.
In November 2021, led by the Bridford Group, LenioBio closes its Series A extension round amounting to 11.5 M. €. Along with the funding round, long-term experts in pharma manufacturing and life sciences joined our Board.
Surrounded by the employees, investors and business partners, LenioBio celebrated its 5th anniversary on September 2021.
Find out more about the event on our Press Release.
LenioBio is awarded the Eurostars grant in June 2021, leading a consortium with two European partners, Wageningen University, The Netherlands, and EnginZyme AB, Sweden. The project goal is to develop the first high-throughput glycoprotein production and manufacturing system, based on the ALiCE® technology.
Continuous research and development allow LenioBio to produce our first batch of 10-liter lysate in September 2021, which is another 10- fold scaling and a major milestone for the company.
Our focus on accelerating the scaling of the ALiCE technology bears its first fruits by end of 2020. LenioBio achieves the first scaling step to 1 liter lysate production.
After the successful launch of our first kit, we focus on accelerating the scaling of the technology, improve further the productivity and robustness, allowing any potential customer lacking cell-fermentation infrastructure to produce clinical trial material.
In March 2019, LenioBio signs a distribution agreement with Merck Millipore Sigma to distribute the ALiCE kit worldwide.
In February 2018, LenioBio acquires the exclusive license from Corteva Agriscience™ (former Dow AgroSciences) to further develop and commercialize the technology across all industries.
Find out more about this agreement.
Born from his dream to produce enough Ebola vaccine quickly for those in urgent need, Dr. Remberto Martis founds LenioBio GmbH in September 2016.
Together with a Business Angel, the foundation of LenioBio is set and an ambitious growth strategy to develop and scale the BYL technology is implemented.
The ALiCE technology has been developed by the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and has been further optimized in the consorted efforts of the Fraunhofer IME and Corteva Agriscience™ (former Dow AgroSciences) to provide an efficient and high-yielding plant-based, cell-free production system for the internal crop development of Corteva Agriscience™ (former Dow AgroSciences).
This technology, named BYL (BY-2 Lysate), was kept as an industry secret and can only be tracked to one small publication in 2015.
The current procedure is largely described in the published patents, which are the basis for the license deals with Fraunhofer IME and Corteva Agriscience™ (former Dow AgroSciences).